Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival
View abstract on PubMed
Summary
This summary is machine-generated.This study explores N6-methyladenosine (m<sup>6</sup>A) modifications in chromophobe renal cell carcinoma (chRCC). We found altered m<sup>6</sup>A regulators and developed a predictive model for chRCC patient survival.
Area Of Science
- Oncology
- Molecular Biology
- Epigenetics
Background
- N6-methyladenosine (m<sup>6</sup>A) is a key mRNA modification influencing various cancers.
- The role of m<sup>6</sup>A in chromophobe renal cell carcinoma (chRCC) is not well understood.
Purpose Of The Study
- To investigate m<sup>6</sup>A alterations in chRCC using advanced sequencing techniques.
- To identify m<sup>6</sup>A regulators, affected genes, and pathways in chRCC.
- To develop a prognostic model for chRCC based on m<sup>6</sup>A-associated gene expression.
Main Methods
- m6A-SEAL-seq and RNA-seq were performed on chRCC and normal tissues.
- Differential expression analysis of m<sup>6</sup>A regulators and genes.
- Pathway enrichment analysis and development of a survival prediction model.
Main Results
- Reduced expression of four m<sup>6</sup>A regulators was observed in chRCC tissues.
- Significant differences in m<sup>6</sup>A levels were detected between chRCC and normal tissues.
- NOTCH1 and FGFR1 were identified as key genes affected by m<sup>6</sup>A alterations.
- A predictive model showed promising prognostic capability for chRCC patient survival.
Conclusions
- m<sup>6</sup>A modifications play a significant role in chRCC development.
- Altered m<sup>6</sup>A regulators and associated genes offer potential therapeutic and diagnostic targets.
- m<sup>6</sup>A-based gene expression signatures can serve as prognostic indicators for chRCC.

